Silexion Therapeutics has begun Good Manufacturing Practice (GMP) clinical batch production of SIL204, a next-generation siRNA therapy targeting mutated KRAS in pancreatic cancer. The Helsinki Ethics Committee at Tel Aviv Sourasky Medical Center approved the planned Phase 2/3 trial, marking a key clinical milestone. Manufacturing is done in collaboration with Catalent at their European facility, supporting the upcoming trial that will test SIL204 combined with chemotherapy. This progress advances Silexion closer to initiating patient dosing and clinical evaluation of SIL204's effectiveness in locally advanced pancreatic cancer.
Quantum Cyber has secured an exclusive license for BP United's autonomous drone technology, including a sky defense platform capable of over 25 km range and fully autonomous operations. This move positions Quantum Cyber to capitalize on the Trump adm...
Brown-Forman, maker of Jack Daniel's, has declined a $15 billion all-cash acquisition offer from competitor Sazerac, which valued the company at $32 per share. This rejection follows the recent end of merger discussions between Brown-Forman and Perno...
Andera Partners led a $20 million Series D funding round for Rivermark Medical, supporting the development and upcoming commercial launch of the FloStent System, a non-surgical, reversible device for treating benign prostatic hyperplasia (BPH). The f...
Sitryx Therapeutics announced positive Phase 1a trial results for SYX-5219, an oral PKM2 modulator targeting atopic dermatitis. The trial in healthy volunteers showed the drug was safe, well tolerated, and demonstrated immune system modulation by red...
Corbus Pharmaceuticals Holdings, a clinical-stage biotech company focused on oncology and obesity therapies, announced CEO Yuval Cohen will present corporate updates and meet investors at two major healthcare conferences in New York: the RBC Capital ...
